Brisbane Clinical Trials

The Release Study

8 nights
12 visits

Study Objective:

  • To evaluate the efficacy of an extended-release version of lanreotide in providing steady medication levels while reducing the frequency of injections.

Understanding Acromegaly:

  • Lanreotide helps regulate hormones, including human growth hormone, making it beneficial for treating conditions like acromegaly, which is caused by excess hormones.

Importance of Treatment:

  • Long-term treatment is often necessary for these hormonal conditions, and an extended-release formulation can potentially improve patient adherence and outcomes.

Clinical Trial Details:

  • The trial focuses on assessing the extended-release lanreotide's ability to maintain drug effectiveness with less frequent dosing.
  • An independent ethics committee has approved this clinical trial.
  • Participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Male or Female
Age 18 - 55 years old
BMI 18 - 32.9kg/m²
Weight >50kg
Medical History No significant medical history
Medication Not taking any prescription medication (except for hormonal contraception)
Smoking History Non-smokers or <10 cigarettes/week in the past 30 days